Norcal Medical Research, Inc.

Norcal Medical Research, Inc. NorCal conducts clinical research in the North SF Bay Area and is enrolling patients in weight loss, diabetes, neuropathy and thyroid studies.

We have extensive experience in state-of-the-art clinical research with leading pharmaceutical companies.

NorCal is currently focused on three exciting weight loss studies involving unique medications being developed to provid...
05/02/2026

NorCal is currently focused on three exciting weight loss studies involving unique medications being developed to provide additional treatment options for individuals with overweight conditions of various degrees and Type 2 diabetes (recruiting now) as well as for persons without diabetes (screening now), and for those with Type 1 diabetes (coming in July)!

These studies may provide special opportunities for those who have not had access to GLP1s, not been able to tolerate the side effects or have not lost significant weight on them.

The Type 1 Diabetes study is a landmark trial as currently there are no GLP-1 type medications approved for weight loss in T1D.

Call with any questions. 415-461-1585

Click on the link to read our May newsletter and find out more about each of the three studies.

https://conta.cc/3PfTGae

NorCal is currently focused on three exciting weight loss studies involving unique medications being developed to provid...
05/02/2026

NorCal is currently focused on three exciting weight loss studies involving unique medications being developed to provide additional treatment options for individuals with overweight conditions of various degrees and Type 2 Diabetes (recruiting now) as well as for persons without diabetes (screening now), and for those with Type 1 Diabetes (coming in July)!

These studies may provide special opportunities for those who have not had access to GLP1s, not been able to tolerate the side effects or have not lost significant weight on them.

This summer we will be studying one of the first weight loss injectables developed specifically for safe weight loss in overweight persons with Type 1 Diabetes.

You can find out more details about all three studies in our May newsletter. Make sure to sign up by clicking on the link at the end of the newsletter if you would like to receive it every month and stay appraised of our studies.

Feel free to call with any questions.

Email from NORCAL Medical Research Linda M. Gaudiani MD   Possibilities today...Treatments Tomorrow MAY 2026   Greetings friends of NorCal and welcome to the May 2026 newsletter! This spring, we conti

The next few months NorCal will be focused on three exciting NEW WEIGHT LOSS STUDIES studies involving unique medication...
04/01/2026

The next few months NorCal will be focused on three exciting NEW WEIGHT LOSS STUDIES studies involving unique medications being developed to provide additional treatment options for (1) individuals with overweight condition and Type 2 diabetes (current) as well as (2) for persons without diabetes (May), and (3) for those with Type 1 diabetes (July)!

Read our April newsletter to find out more and/or contact us at 415-461-1585 for additional info and to see if you may qualify.

Email from NORCAL Medical Research Linda M. Gaudiani MD   Possibilities today...Treatments Tomorrow APRIL 2026   Greetings friends of NorCal! Welcome to NorCal’s April 2026 newsletter. I continue to b

02/23/2026

Interested in LOSING WEIGHT? The newest weight loss medications? Life style strategies for optimizing your health?

NorCal Medical Research studies the latest medications for sustainable, safe weight loss in adults without diabetes and in persons with Type 1 and Type 2 Diabetes!

Participants receive:
• Free metabolic screening, blood tests, EKGs, body composition studies and more
• Access to study weight loss medications at no cost
• Life style support and dietary coaching
• Meticulous study-related care and monitoring from medical experts
• Compensation for time and travel
• Coordination with your primary practitioners

Let us give you more info at: 📞 415-461-1585 📧 [email protected] 🌐 NorCalMedicalResearch.com Linda M Gaudiani MD FACP FACE Medical Director

NorCal conducts clinical research in the North SF Bay Area and is enrolling patients in weight loss, diabetes, neuropathy and thyroid studies. We have extensive experience in state-of-the-art clinical research with leading pharmaceutical companies.

NorCal is excited to be enrolling patients in a new clinical trial for eloralintide, a long-acting form of the hormone a...
02/11/2026

NorCal is excited to be enrolling patients in a new clinical trial for eloralintide, a long-acting form of the hormone amylin which has benefits similar to the GLP-1s. We are also now offering free metabolic screening including free HA1C, finger stick blook sugar tests and more for anyone concerned about their risk of prediabetes or diabetes.

For more details, check out our February newsletter and contact us at 415-461-1585 with any questions or to make an appointment.

Email link

Email from NORCAL Medical Research Linda M. Gaudiani MD   Possibilities today...Treatments Tomorrow FEBRUARY 2026   Greetings friends of NorCal! Welcome to our February 2026 newsletter. Starting immed

THYROID CLINICAL STUDY ENDING ON JANUARY 30!!!Have you thought about exploring a safe thyroid replacement therapy other ...
01/25/2026

THYROID CLINICAL STUDY ENDING ON JANUARY 30!!!
Have you thought about exploring a safe thyroid replacement therapy other than the standard levothyroxine you may be taking now?
The study compares naturally derived thyroid replacement therapy as Armour thyroid to synthetic levothyroxine for individuals with hypothyroidism. Armour is made from purified thyroid extract and contains both T4 and T3 thyroid hormones.
Call us right away at 415-461-1585 to find out more details about the study while there is still time to enroll.

Our FALL newsletter highlights exciting clinical trials for weight loss and hypothyroidism. We're currently recruiting p...
10/28/2025

Our FALL newsletter highlights exciting clinical trials for weight loss and hypothyroidism. We're currently recruiting participants for a study on eloralintide, a promising new weight loss drug for persons with type 2 diabetes, and exploring alternative thyroid treatments. Call us at 415.461.1585 to learn more about our studies and how you can participate.

https://conta.cc/46RF3Qv

New weight loss study for people with Type 2 Diabetes! Call 415-461-1585 for details!
10/11/2025

New weight loss study for people with Type 2 Diabetes! Call 415-461-1585 for details!

NorCal is conducting a clinical trial to compare Armour desiccated animal thyroid with synthetic levothyroxine for treat...
08/18/2025

NorCal is conducting a clinical trial to compare Armour desiccated animal thyroid with synthetic levothyroxine for treatment of hypothyroidism. If you have hypothyroidism and are on a stable daily dose of levothyroxine, you may qualify to participate. To learn more about our study check out our August newsletter.

Contact us at 415-461-1585 or [email protected].



https://conta.cc/4n9hJTR

Email from Linda M. Gaudiani MD   Possibilities today...Treatments Tomorrow AUGUST 2025   If you know someone who might benefit from this newsletter, please forward it to them! Greetings friends of N

We just published our summer newsletter! Find out about our new weight loss study for persons with type 2 diabetes: it i...
06/10/2025

We just published our summer newsletter! Find out about our new weight loss study for persons with type 2 diabetes: it is testing a new ORAL GLP-1 medication to help with weight loss and HA1C lowering. Our medical director also discusses one of her favorite topics: the importance of nutritional and lifestyle counseling when losing weight. https://conta.cc/447i6r0

Address

900 South Eliseo Drive, Suite 103
Greenbrae, CA
94904

Alerts

Be the first to know and let us send you an email when Norcal Medical Research, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Norcal Medical Research, Inc.:

Share